Clinical Trials on Hereditary Breast and Ovarian Cancer in United Kingdom

Total 23962 results

National Human Genome Research Institute (NHGRI)

Completed

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

Breast Cancer

United States
Abramson Cancer Center at Penn Medicine

Enrolling by invitation

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

Ovarian Cancer | Genetic Predisposition to Disease | Breast Cancer Female | Hereditary Diseases | Gene Mutation-Related Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome

United States
University of Kansas Medical Center

Recruiting

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)

Breast Cancer | Hereditary Breast and Ovarian Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
University of Southern California
Stanford University

Completed

Cancer Genetics Hereditary Cancer Panel Testing (HCP)

Hereditary Breast and Ovarian Cancer

United States
Georgetown University
Virginia Commonwealth University; Cornell University

Completed

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Hereditary Breast and Ovarian Cancer

United States
Emory University

Completed

Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer

Hereditary Breast and Ovarian Cancer

United States
Georgetown University

Completed

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Hereditary Breast and Ovarian Cancer

United States
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
M.D. Anderson Cancer Center

Completed

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Breast Cancer | Ovarian Cancer

United States
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Cedars-Sinai Medical Center
Sientra, Inc.

Completed

Tissue Expansion in Breast Reconstruction Without Drains

Breast Cancer | Hereditary Breast and Ovarian Cancer Syndrome | Breast Implant; Complications

United States
Johns Hopkins University
National Human Genome Research Institute (NHGRI)

Completed

Genetic Risk: Whether, When, and How to Tell Adolescents

Huntington Disease | Hereditary Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Non-polyposis Colon Cancer | Hereditary Non-Polyposis Colorectal Cancer Syndrome

United States
University College London Hospitals

Completed

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation Carrier

Australia, Israel, United Kingdom, Spain, Sweden, Portugal
Georgetown University
National Cancer Institute (NCI); Virginia Commonwealth University

Enrolling by invitation

CONTIGO - Informing Latinas About HBOC Risk

Hereditary Breast and Ovarian Cancer

United States
Aspira Women's Health

Terminated

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection (OVA360)

Hereditary Breast and Ovarian Cancer | Adnexal Mass | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation

United States
Georgetown University
Virginia Commonwealth University; Basser Center for BRCA; Nueva Vida, Inc.; Capital... and other collaborators

Completed

Enhance the Use of Genetic Counseling and Testing in Latinas

Hereditary Breast and Ovarian Cancer Syndrome

United States
Georgetown University
National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)

Completed

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2)

United States
The National Institute of Lymphology
The DrMarga Practice Group; The Center for Restorative Breast Surgery, LLC

Unknown

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired Lymphedema

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Fallopian Tube Carcinoma | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome | Primary Peritoneal Carcinoma

United States
Eve Rodler

Not yet recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Breast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Genetics and Heart Health After Cancer Therapy (Gene-HEART)

Heart Diseases | Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Drug-Induced Cardiomyopathy

United States
Boston University
National Institute on Minority Health and Health Disparities (NIMHD); University... and other collaborators

Recruiting

Scalable Communication Modalities for Returning Genetic Research Results (BWHS RoR)

Lynch Syndrome | Hereditary Breast and Ovarian Cancer

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Triple Negative Breast Cancer | Advanced Ovarian Cancer

United Kingdom, United States, Australia, Denmark, Canada
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital

Terminated

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Lynch Syndrome | Hereditary Breast and Ovarian Cancer

United States
University of Oxford

Completed

A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours (6MP)

Breast Cancer | Ovarian Cancer

United Kingdom
National Cancer Institute (NCI)

Completed

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Hereditary Breast and Ovarian Cancer Syndrome | Adult Solid Neoplasm | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
AstraZeneca

Active, not recruiting

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Advanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast Cancer

Belgium, Netherlands, United Kingdom
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

Stage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Breast Cancer | Gynecologic Cancer | Pancreatic Cancer | Lynch Syndrome | Endometrial Cancer | Colon Cancer | Hereditary Breast and Ovarian Cancer Syndrome | Uterus Cancer | Ovary Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Recruiting

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Malignant Solid Neoplasm | Lynch Syndrome | Hematopoietic and Lymphoid System Neoplasm | Breast Ductal Carcinoma In Situ | Hereditary Neoplastic Syndrome | BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Osteoporosis | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome

United States
Duke University
Susan G. Komen Breast Cancer Foundation

Completed

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Lynch Syndrome | Hereditary Breast and Ovarian Cancer Syndrome

United States
University of Washington
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Ovarian Epithelial Cancer | Stage III Ovarian Germ Cell Tumor

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditions

United States
Cancer Research UK

Completed

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Breast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United Kingdom
University of California, San Diego
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients (POISE)

Breast Cancer | Ovarian Failure | Ovarian Insufficiency

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
NYU Langone Health

Recruiting

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

MLH1 Gene Mutation | RAD51C Gene Mutation | BRIP1 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | BRCA-Mutated Ovarian Carcinoma | MSH2 A636P | EPCAM

United States
Dana-Farber Cancer Institute
Novartis

Terminated

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer | HER2-Negative Breast Cancer | Metastatic Epithelial Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Fallopian Tube Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Female Reproductive Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Swedish Medical Center
GlaxoSmithKline

Completed

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Stage IV Breast Cancer | Stage IV Ovarian Cancer | Ovarian Epithelial Cancer Stage III

United States
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Janssen Research & Development, LLC

Completed

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Neoplasms | Neoplasms, Breast | Neoplasms, Ovarian | Advanced or Refractory Solid Malignancies

United States, United Kingdom, Spain, Belgium
Imperial College London
Medical Research Council; ECMC

Recruiting

D4 Choline Breast PET/CT

Metastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer

United Kingdom
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

Korea, Republic of, United Kingdom, Australia, United States, Spain
Indiana University
Breast Cancer Research Foundation

Withdrawn

Breast Cancer BRCA1 Carriers: a Pilot Study

High-grade Serous Ovarian Cancer | BRCA1 Mutation | TNBC - Triple-Negative Breast Cancer

United States
Genmab

Recruiting

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Squamous Non Small Cell Lung Cancer (NSCLC-SCC) | Breast Cancer, Breast Neoplasms | Endometrial Cancer, Endometrial Neoplasm | Ovarian Cancer, Ovarian Neoplasms

United States, France, Spain, Netherlands, Belgium, United Kingdom, Denmark, Italy, Poland

Clinical Trials on Hereditary Breast and Ovarian Cancer in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations